- Home
- SGD vs TCRT Comparison
SGD vs TCRT Comparison
Compare SGD & TCRT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SGD
- TCRT
- Stock Information
- Founded
- SGD 2021
- TCRT 1998
- Country
- SGD United States
- TCRT United States
- Employees
- SGD N/A
- TCRT N/A
- Industry
- SGD
- TCRT Biotechnology: Pharmaceutical Preparations
- Sector
- SGD
- TCRT Health Care
- Exchange
- SGD Nasdaq
- TCRT Nasdaq
- Market Cap
- SGD 4.4M
- TCRT 4.8M
- IPO Year
- SGD N/A
- TCRT N/A
- Fundamental
- Price
- SGD $1.31
- TCRT $2.33
- Analyst Decision
- SGD
- TCRT
- Analyst Count
- SGD 0
- TCRT 0
- Target Price
- SGD N/A
- TCRT N/A
- AVG Volume (30 Days)
- SGD 375.7K
- TCRT 339.2K
- Earning Date
- SGD 08-15-2025
- TCRT 11-13-2025
- Dividend Yield
- SGD N/A
- TCRT N/A
- EPS Growth
- SGD N/A
- TCRT N/A
- EPS
- SGD N/A
- TCRT N/A
- Revenue
- SGD $1,536,255.00
- TCRT $6,000.00
- Revenue This Year
- SGD N/A
- TCRT $5,680,500.00
- Revenue Next Year
- SGD N/A
- TCRT N/A
- P/E Ratio
- SGD N/A
- TCRT N/A
- Revenue Growth
- SGD 1570.24
- TCRT N/A
- 52 Week Low
- SGD $0.65
- TCRT $1.31
- 52 Week High
- SGD $6.25
- TCRT $6.20
- Technical
- Relative Strength Index (RSI)
- SGD 53.56
- TCRT 51.13
- Support Level
- SGD $1.02
- TCRT N/A
- Resistance Level
- SGD $1.80
- TCRT $2.39
- Average True Range (ATR)
- SGD 0.15
- TCRT 0.19
- MACD
- SGD 0.02
- TCRT -0.01
- Stochastic Oscillator
- SGD 47.37
- TCRT 95.29
About SGD Safe and Green Development Corporation
Safe & Green Development Corp is a real estate development company that focuses on the development of sites using purpose built, prefabricated modules built from both wood & steel, sourced from one of Safe and Green Holdings factories. The company's business model is flexible and it anticipates developing properties on its own and also through joint ventures in which it partners with third-party equity investors or other developers.
About TCRT Alaunos Therapeutics Inc.
Alaunos Therapeutics Inc is a clinical-stage cellular immuno-oncology company dedicated to the treatment of solid tumors through adoptive TCR-T cell therapy. It strikes cancer at its core by engineering cell therapies that target Neoantigens arising from genomic mutations. It has a single reportable and operating segment related to biopharmaceutical research and development.